http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004076609-A1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-50 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 |
filingDate | 2003-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7737ac860eaedf39b52ce120b84b8745 |
publicationDate | 2004-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2004076609-A1 |
titleOfInvention | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
abstract | Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009517474-A |
priorityDate | 1999-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 518.